Arbutus Biopharma Co. (NASDAQ:ABUS – Get Free Report) was the recipient of some unusual options trading on Wednesday. Traders bought 14,379 call options on the stock. This is an increase of approximately 1,406% compared to the average daily volume of 955 call options.
Analyst Upgrades and Downgrades
ABUS has been the subject of several analyst reports. JMP Securities upped their target price on Arbutus Biopharma from $4.00 to $5.00 and gave the company a “market outperform” rating in a report on Friday, August 2nd. Jefferies Financial Group raised their price objective on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. Finally, StockNews.com upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 10th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Arbutus Biopharma has a consensus rating of “Moderate Buy” and an average price target of $5.25.
Check Out Our Latest Stock Analysis on ABUS
Institutional Trading of Arbutus Biopharma
Arbutus Biopharma Trading Up 2.2 %
NASDAQ ABUS opened at $4.20 on Thursday. Arbutus Biopharma has a twelve month low of $1.69 and a twelve month high of $4.72. The stock has a fifty day simple moving average of $3.97 and a 200-day simple moving average of $3.46.
Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Arbutus Biopharma had a negative net margin of 766.20% and a negative return on equity of 66.68%. The company had revenue of $1.73 million for the quarter, compared to analyst estimates of $1.54 million. During the same quarter in the prior year, the business earned ($0.10) earnings per share. As a group, equities research analysts expect that Arbutus Biopharma will post -0.38 earnings per share for the current year.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
See Also
- Five stocks we like better than Arbutus Biopharma
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- High Flyers: 3 Natural Gas Stocks for March 2022
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.